Look at Total Prescribing Details OPDIVO® (nivolumab) is indicated with the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed soon after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or soon after three or even more lines of systemic therapy that includes a… Read More